Cas 910463-68-2 Semaglutide Medicine Peptide 98% Powder for Weight Loss

Semaglutide is a new generation of GLP-1 (Chemicalbook glucagon-like peptide-1) analogs developed by Novo Nordisk, Denmark. Semaglutide is based on liraglutide. The long-acting dosage form developed by the structure of the drug has a better effect on the treatment of type 2 diabetes.

1. Semaglutide powder Basic Information

2.Product Introduction

Semeglutide is a novel once-weekly subcutaneous GLP-1 analog. Semaglutide is a 1/w subcutaneous long-acting GLP-1 analog developed by Novo Nordisk. Compared with liraglutide, semaglutide has a longer aliphatic chain and increased hydrophobicity, but semaglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

3.Dosage and Usage

The initial dose of this product is 0.25 mg, subcutaneously, once a week for 4 consecutive weeks; thereafter, the dose is increased to 0.5 mg each time; if the blood sugar control is not good, the 0.5 mg dose is maintained for 4 weeks and then increased to the maximum dose each time 1 mg once a week. It can be administered at any time of the week, but the interval between two administrations should be more than 2 days. If the dose is missed, the injection should be supplemented within 5 days; if more than 5 days, the next dose should be given according to the original plan.

4.Special population

The safety and efficacy of semaglutide in pediatric patients have not been established, and its use is not recommended. No overall differences in safety or efficacy were observed with semaglutide for the treatment of patients with type 2 diabetes, subjects over the age of 65 years, and younger subjects, but greater sensitivity in individual elderly patients cannot be ruled out. sex. In patients with mild, moderate or severe hepatic or renal impairment, there is no clinically meaningful difference in kinetics compared with healthy subjects, so no dose adjustment is required.

At present, there is no sufficient data on the use of this product in pregnant women. Animal studies have shown that this product has reproductive toxicity. The potential risk of this product to humans is not known. It is recommended that this product should not be used during pregnancy. If the patient plans to become pregnant during treatment If you are pregnant, you should stop treatment with this product. In addition, due to the presence of semaglutide in the milk of rabbits, this product should not be used while the patient is breastfeeding.

5.Adverse drug reaction

Common adverse reactions (incidence greater than 5%) due to semaglutide include nausea, vomiting, diarrhea, and constipation.

6.Medicine interactions

In vitro experiments confirmed that semaglutide does not inhibit or induce CYP enzymes, nor does it interact with drug transporters. Semaglutide can cause delayed gastric emptying and can reduce the rate and extent of absorption of oral drugs when co-administered with oral drugs. Semaglutide has not been known to interact with metformin, atorvastatin, warfarin, digoxin, or oral contraceptives.

http://www.senwayerpeptide.com/